Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511484 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL29409577 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31749859 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31355501 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL178765 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL259018 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL1593608 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL4557247 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31309927 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL29634951 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216526-A1 | PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF | CHENGDU SCIMOUNT PHARMATECH CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-7598421-B2 | Materials for the delivery of biologically-active material to cells | UCL BIOMEDICA PLC (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598421-B2 | Materials for the delivery of biologically-active material to cells | UCL BIOMEDICA PLC (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598421-B2 | Materials for the delivery of biologically-active material to cells | UCL BIOMEDICA PLC (GB) | 2009-10-06 | — | — | US | disclosed |
| US-20050245446-A1 | Materials for the delivery of biologically-active material to cells | NANOGENICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245446-A1 | Materials for the delivery of biologically-active material to cells | ITGB1, ITGA2B, ITGB2 | KMT2A 4254/4885SMN1; SMN2 2326/4885LMNA 105/4885 |
| US-20240216526-A1 | PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF | SKP1, ADCY7, ERBB2 | KMT2A 1387/4885SMN1; SMN2 1784/4885LMNA 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.